Your browser is no longer supported. Please, upgrade your browser.
Emergent BioSolutions Inc.
Index- P/E34.18 EPS (ttm)3.11 Insider Own2.50% Shs Outstand53.00M Perf Week9.32%
Market Cap5.84B Forward P/E11.91 EPS next Y8.92 Insider Trans-14.77% Shs Float45.20M Perf Month19.04%
Income166.60M PEG3.71 EPS next Q2.83 Inst Own83.60% Short Float4.58% Perf Quarter6.77%
Sales1.33B P/S4.38 EPS this Y-8.50% Inst Trans0.26% Short Ratio3.75 Perf Half Y2.01%
Book/sh23.61 P/B4.50 EPS next Y27.00% ROA6.90% Target Price111.29 Perf Year89.67%
Cash/sh7.56 P/C14.07 EPS next 5Y9.20% ROE14.40% 52W Range46.37 - 137.61 Perf YTD18.63%
Dividend- P/FCF21.47 EPS past 5Y-2.60% ROI4.80% 52W High-22.76% Beta1.25
Dividend %- Quick Ratio2.30 Sales past 5Y22.30% Gross Margin64.40% 52W Low129.22% ATR4.48
Employees1834 Current Ratio3.20 Sales Q/Q23.50% Oper. Margin19.00% RSI (14)66.98 Volatility4.17% 4.38%
OptionableYes Debt/Eq0.70 EPS Q/Q-11.90% Profit Margin12.50% Rel Volume0.94 Prev Close105.99
ShortableYes LT Debt/Eq0.68 EarningsNov 05 AMC Payout0.00% Avg Volume551.25K Price106.29
Recom1.90 SMA2010.29% SMA5018.44% SMA20015.72% Volume518,545 Change0.28%
Jan-08-21Downgrade Wells Fargo Overweight → Equal Weight $110
Sep-14-20Resumed JP Morgan Neutral $103
Jul-31-20Reiterated Chardan Capital Markets Buy $86 → $112
Sep-12-19Initiated Guggenheim Buy
Sep-04-19Upgrade Wells Fargo Market Perform → Outperform
Nov-02-18Upgrade Goldman Neutral → Buy
Aug-03-18Reiterated Chardan Capital Markets Buy $53 → $57
Jun-13-18Initiated Argus Buy $62
Apr-25-18Downgrade Wells Fargo Outperform → Market Perform
Jan-24-18Initiated Goldman Neutral
Jan-16-18Reiterated Chardan Capital Markets Buy $47 → $53
Jun-28-16Reiterated Singular Research Buy $44 → $40
Apr-15-16Initiated Chardan Capital Markets Buy $47
Mar-28-16Initiated Singular Research Buy $44
Feb-19-16Initiated Wells Fargo Outperform
May-15-14Initiated Summer Street Research Buy $35
May-31-11Reiterated WBB Securities Strong Buy $20.50 → $30
Jan-10-11Reiterated Wedbush Outperform $27 → $32
Nov-05-10Reiterated Wedbush Outperform $22 → $27
Aug-18-10Upgrade WBB Securities Buy → Strong Buy $20.50
Jan-13-21 01:38PM  
Jan-12-21 10:37AM  
Jan-11-21 09:22AM  
Jan-10-21 02:00PM  
Jan-07-21 12:45PM  
Jan-06-21 05:50PM  
Jan-05-21 07:03AM  
Jan-04-21 03:25PM  
Dec-31-20 09:40AM  
Dec-30-20 11:21AM  
Dec-29-20 04:05PM  
Dec-18-20 08:15PM  
Dec-17-20 09:19AM  
Dec-16-20 11:56PM  
Dec-15-20 09:38AM  
Dec-05-20 11:32AM  
Dec-02-20 12:35PM  
Nov-27-20 06:14AM  
Nov-18-20 09:30AM  
Nov-10-20 09:40AM  
Nov-09-20 10:18AM  
Nov-06-20 06:50PM  
Nov-05-20 07:40PM  
Nov-04-20 09:52AM  
Nov-03-20 10:29AM  
Nov-02-20 12:46PM  
Oct-30-20 03:54PM  
Oct-29-20 05:45PM  
Oct-28-20 10:32AM  
Oct-23-20 05:45PM  
Oct-21-20 11:30AM  
Oct-20-20 10:26AM  
Oct-19-20 10:09AM  
Oct-16-20 09:58AM  
Oct-15-20 05:45PM  
Oct-14-20 10:03AM  
Oct-13-20 12:31PM  
Oct-12-20 09:45AM  
Oct-09-20 08:40AM  
Oct-08-20 04:05PM  
Oct-07-20 10:49AM  
Oct-06-20 09:19AM  
Oct-05-20 12:46PM  
Sep-21-20 04:25AM  
Sep-18-20 11:30AM  
Sep-16-20 12:19PM  
Sep-15-20 10:48AM  
Sep-11-20 05:50PM  
Sep-10-20 12:11PM  
Sep-08-20 04:34AM  
Sep-04-20 11:41AM  
Sep-02-20 11:30AM  
Sep-01-20 10:10AM  
Aug-31-20 06:30AM  
Aug-29-20 11:31AM  
Aug-26-20 01:33PM  
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
El-Hibri FuadChairmanNov 10Option Exercise26.4519,391512,8921,143,379Nov 12 06:30 PM
El-Hibri FuadChairmanNov 10Sale88.2119,3911,710,4801,123,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 09Option Exercise26.4520,000529,0001,143,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 09Sale95.2620,0001,905,2001,123,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 03Option Exercise26.4520,000529,0001,143,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 03Sale90.7420,0001,814,8001,123,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 02Option Exercise26.4520,000529,0001,143,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 02Sale90.4420,0001,808,8001,123,988Nov 04 08:53 PM
El-Hibri FuadChairmanSep 24Sale98.8512,5351,239,0851,123,988Sep 25 07:00 PM
El-Hibri FuadChairmanSep 23Sale100.5813,0001,307,5401,136,523Sep 25 07:00 PM
El-Hibri FuadChairmanSep 17Sale100.6820,0002,013,6001,149,523Sep 18 06:25 PM
El-Hibri FuadChairmanSep 16Sale102.4820,0002,049,6001,169,523Sep 18 06:25 PM
El-Hibri FuadChairmanSep 10Sale102.6620,0002,053,2001,189,523Sep 11 09:21 PM
El-Hibri FuadChairmanSep 09Sale102.8020,0002,056,0001,209,523Sep 11 09:21 PM
SULLIVAN LOUIS WDirectorSep 02Option Exercise20.087,893158,49150,655Sep 04 08:08 PM
SULLIVAN LOUIS WDirectorSep 02Sale111.2228,4183,160,60642,762Sep 04 08:08 PM
Bailey SueDirectorAug 18Sale128.314,665598,56432,595Aug 19 05:08 PM
Harsanyi ZsoltDirectorAug 17Sale133.716,609883,66424,579Aug 18 09:12 AM
JOULWAN GEORGE ADirectorAug 11Sale124.116,000744,63526,771Aug 12 04:52 PM
Zoon Kathryn CDirectorAug 10Sale130.271,000130,27012,489Aug 11 04:43 PM
Richard RonaldDirectorAug 07Sale131.006,297824,9078,276Aug 11 04:46 PM
Richard RonaldDirectorJun 03Sale87.516,572575,1424,269Jun 05 04:36 PM
Bailey SueDirectorJun 03Sale87.505,322465,69137,260Jun 05 04:33 PM
Hauer Jerome MDirectorMay 26Sale85.154,385373,37310,188May 27 05:10 PM
Zoon Kathryn CDirectorMay 26Sale85.104,093348,32213,489May 27 05:07 PM
Harsanyi ZsoltDirectorMay 14Option Exercise18.643,43464,01028,367May 18 07:12 PM
Zoon Kathryn CDirectorMay 12Sale85.211,660141,45414,761May 14 04:30 PM
Harsanyi ZsoltDirectorMay 11Sale81.994,940405,02524,933May 13 07:47 PM
JOULWAN GEORGE ADirectorMay 11Sale85.192,000170,37129,950May 13 07:45 PM
Richard RonaldDirectorMay 05Sale80.198,375671,6298,020May 06 05:08 PM
El-Hibri FuadChairmanApr 30Sale74.0120,0001,480,2001,229,523May 01 08:13 PM
El-Hibri FuadChairmanApr 29Sale74.2420,0001,484,8001,249,523May 01 08:13 PM
Richard RonaldDirectorApr 27Option Exercise20.087,893158,49124,288Apr 29 04:35 PM
Richard RonaldDirectorApr 27Sale78.007,893615,65416,395Apr 29 04:35 PM
El-Hibri FuadChairmanApr 23Sale68.4920,0001,369,8001,269,523Apr 24 04:16 PM
El-Hibri FuadChairmanApr 22Sale66.8120,0001,336,2001,289,523Apr 24 04:16 PM
Havey AdamEVP, Business OperationsApr 20Option Exercise30.8617,009524,89851,265Apr 21 06:12 PM
Havey AdamEVP, Business OperationsApr 20Sale69.0017,0091,173,62134,256Apr 21 06:12 PM
Havey AdamEVP, Business OperationsApr 17Option Exercise26.4520,414539,95054,670Apr 21 06:12 PM
Havey AdamEVP, Business OperationsApr 17Sale65.0020,4141,326,91034,256Apr 21 06:12 PM
El-Hibri FuadChairmanApr 16Sale62.4720,0001,249,4001,309,523Apr 20 06:30 PM
El-Hibri FuadChairmanApr 15Sale62.5812,537784,5651,329,523Apr 15 09:04 PM
El-Hibri FuadChairmanApr 14Sale62.996,261394,3801,342,060Apr 15 09:04 PM
El-Hibri FuadChairmanApr 13Sale62.2517,0711,062,6701,348,321Apr 15 09:04 PM
El-Hibri FuadChairmanApr 09Sale61.8323,7161,466,3601,365,392Apr 10 07:13 PM
El-Hibri FuadChairmanApr 08Sale61.1337,3622,284,1151,389,108Apr 10 07:13 PM
El-Hibri FuadChairmanApr 07Sale60.7614,336871,0551,426,470Apr 08 09:17 PM
Kirk SeanEVP, Manufacturing & Tech OpsApr 06Option Exercise30.7010,428320,13119,864Apr 08 08:19 PM
El-Hibri FuadChairmanApr 06Sale60.5028,2401,708,5201,440,806Apr 08 09:17 PM
Havey AdamEVP, Business OperationsApr 06Sale60.007,972478,32034,256Apr 08 08:22 PM
Kirk SeanEVP, Manufacturing & Tech OpsApr 06Sale60.0016,094965,64012,571Apr 08 08:19 PM
Harsanyi ZsoltDirectorMar 16Sale65.006,400416,00029,873Mar 17 04:39 PM
SULLIVAN LOUIS WDirectorMar 04Option Exercise13.8615,786218,71568,359Mar 06 04:37 PM
Zoon Kathryn CDirectorMar 04Sale60.6599160,10316,421Mar 06 04:39 PM
SULLIVAN LOUIS WDirectorMar 04Sale58.9615,786930,71460,466Mar 06 04:37 PM
Bailey SueDirectorFeb 27Sale56.936,572374,13239,761Mar 02 05:28 PM
El-Hibri FuadChairmanFeb 27Sale56.979,837560,4141,469,046Feb 28 08:01 PM
El-Hibri FuadChairmanFeb 26Sale58.7013,619799,4351,472,943Feb 28 08:01 PM
El-Hibri FuadChairmanFeb 21Option Exercise25.6218,567475,6871,497,585Feb 24 08:00 PM
Richard RonaldDirectorFeb 21Option Exercise18.645,15296,03331,851Feb 25 04:30 PM
Richard RonaldDirectorFeb 21Sale65.005,152334,88016,395Feb 25 04:30 PM
Hauer Jerome MDirectorFeb 21Sale70.006,572460,04011,752Feb 25 04:28 PM
El-Hibri FuadChairmanFeb 21Sale64.9018,5671,204,9981,479,018Feb 24 08:00 PM
El-Hibri FuadChairmanFeb 20Option Exercise25.624,751121,7211,483,769Feb 24 08:00 PM
El-Hibri FuadChairmanFeb 20Sale64.904,751308,3401,479,018Feb 24 08:00 PM
El-Hibri FuadChairmanFeb 18Option Exercise25.6215,614400,0311,494,632Feb 19 09:00 PM
El-Hibri FuadChairmanFeb 18Sale63.9015,614997,7351,479,018Feb 19 09:00 PM
El-Hibri FuadChairmanFeb 14Option Exercise25.624,386112,3691,483,404Feb 19 09:00 PM
El-Hibri FuadChairmanFeb 14Sale63.904,386280,2651,479,018Feb 19 09:00 PM
El-Hibri FuadChairmanFeb 12Option Exercise25.6213,720351,5061,492,738Feb 13 06:30 PM
El-Hibri FuadChairmanFeb 12Sale62.9013,720862,9881,479,018Feb 13 06:30 PM
El-Hibri FuadChairmanFeb 11Option Exercise25.626,280160,8941,485,298Feb 13 06:30 PM
El-Hibri FuadChairmanFeb 11Sale62.906,280395,0121,479,018Feb 13 06:30 PM
El-Hibri FuadExecutive ChairmanFeb 06Sale61.9011,684723,2401,419,018Feb 07 06:31 PM
El-Hibri FuadExecutive ChairmanFeb 05Sale60.6648,3162,930,8491,430,702Feb 07 06:31 PM
APVO Aptevo Therapeutics Inc. daily Stock Chart
Aptevo Therapeutics Inc.
Index- P/E- EPS (ttm)-10.15 Insider Own5.93% Shs Outstand3.23M Perf Week-13.10%
Market Cap131.67M Forward P/E- EPS next Y-5.29 Insider Trans- Shs Float1.35M Perf Month-20.40%
Income-32.90M PEG- EPS next Q-1.22 Inst Own75.20% Short Float12.28% Perf Quarter361.46%
Sales11.00M P/S11.97 EPS this Y54.10% Inst Trans180.29% Short Ratio0.09 Perf Half Y314.67%
Book/sh0.68 P/B47.81 EPS next Y-16.00% ROA-56.10% Target Price- Perf Year234.12%
Cash/sh6.15 P/C5.29 EPS next 5Y- ROE-199.50% 52W Range2.94 - 60.00 Perf YTD-11.30%
Dividend- P/FCF- EPS past 5Y15.40% ROI- 52W High-45.82% Beta7.49
Dividend %- Quick Ratio- Sales past 5Y-6.60% Gross Margin44.10% 52W Low1004.20% ATR2.33
Employees80 Current Ratio4.10 Sales Q/Q- Oper. Margin- RSI (14)36.67 Volatility6.40% 6.63%
OptionableNo Debt/Eq11.45 EPS Q/Q37.40% Profit Margin- Rel Volume0.04 Prev Close33.82
ShortableYes LT Debt/Eq11.45 Earnings- Payout- Avg Volume1.79M Price32.51
Recom1.70 SMA20-11.18% SMA50-15.96% SMA200120.02% Volume73,145 Change-3.87%
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Jan-11-21 08:00AM  
Jan-06-21 12:00PM  
Dec-19-20 01:45PM  
Dec-02-20 08:00AM  
Nov-20-20 07:37AM  
Nov-19-20 04:15PM  
Nov-16-20 08:00AM  
Nov-10-20 08:40AM  
Nov-09-20 09:00AM  
Nov-08-20 11:15PM  
Nov-03-20 09:00AM  
Sep-01-20 09:00AM  
Aug-14-20 09:00AM  
Aug-06-20 09:00AM  
Jul-21-20 09:00AM  
Jun-30-20 12:00PM  
Jun-29-20 09:00AM  
Jun-25-20 09:00AM  
Jun-10-20 09:00AM  
May-13-20 09:00AM  
Apr-14-20 09:00AM  
Mar-25-20 09:00AM  
Mar-16-20 09:00AM  
Feb-28-20 09:05AM  
Jan-30-20 09:00AM  
Jan-13-20 08:00AM  
Dec-19-19 03:50PM  
Dec-06-19 09:00AM  
Nov-12-19 09:00AM  
Nov-08-19 09:00AM  
Nov-07-19 09:00AM  
Oct-04-19 07:32AM  
Oct-03-19 04:02PM  
Sep-19-19 09:00AM  
Aug-09-19 09:00AM  
Aug-07-19 09:02AM  
Jul-25-19 04:32PM  
Jun-25-19 09:00AM  
May-09-19 09:00AM  
Apr-29-19 10:21AM  
Apr-26-19 08:31AM  
Apr-15-19 09:00AM  
Apr-11-19 12:26PM  
Apr-02-19 09:02AM  
Mar-25-19 09:02AM  
Mar-20-19 09:02AM  
Mar-18-19 09:00AM  
Mar-14-19 10:28AM  
Mar-07-19 09:13AM  
Mar-06-19 04:37PM  
Jan-07-19 08:30AM  
Jan-03-19 09:02AM  
Dec-21-18 09:00AM  
Dec-20-18 12:57PM  
Dec-13-18 09:02AM  
Dec-11-18 07:20AM  
Nov-20-18 09:00AM  
Nov-14-18 04:02PM  
Nov-09-18 12:00AM  
Oct-24-18 09:00AM  
Oct-10-18 08:40AM  
Sep-25-18 11:29AM  
Sep-05-18 11:36AM  
Aug-31-18 02:46PM  
Aug-09-18 09:00AM  
Aug-07-18 09:00AM  
Aug-06-18 08:10AM  
May-29-18 09:00AM  
May-15-18 07:40AM  
May-10-18 09:00AM  
May-08-18 09:02AM  
May-01-18 09:00AM  
Apr-30-18 07:50AM  
Apr-20-18 08:35PM  
Apr-16-18 09:02AM  
Mar-19-18 08:20AM  
Mar-13-18 09:02AM  
Mar-12-18 09:02AM  
Feb-27-18 09:02AM  
Jan-17-18 08:10AM  
Jan-11-18 09:04AM  
Jan-08-18 09:00AM  
Jan-03-18 08:17AM  
Dec-27-17 10:58AM  
Dec-19-17 09:05AM  
Dec-11-17 01:28PM  
Nov-29-17 10:58AM  
Nov-28-17 07:02AM  
Nov-21-17 06:39PM  
Nov-14-17 04:02PM  
Nov-09-17 04:30PM  
Nov-01-17 11:50AM  
Oct-30-17 09:02AM  
Oct-24-17 09:00AM  
Oct-16-17 09:02AM  
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TANG KEVIN C10% OwnerNov 06Buy22.73174,2773,961,8981,760,000Nov 06 04:47 PM
TANG KEVIN C10% OwnerNov 05Buy18.78625,72311,750,3071,585,723Nov 06 04:47 PM
TANG KEVIN C10% OwnerNov 04Buy14.35636,6759,137,026960,000Nov 06 04:47 PM